```html

Ovalocytosis – A Complete Patient‑Centred Guide

Overview

Ovalocytosis (also called hereditary ovalocytosis or Southeast Asian ovalocytosis, SAO) is a rare inherited disorder of the red blood cell (RBC) membrane that causes the cells to become rigid and oval‑shaped rather than the normal flexible disc shape. The condition is most common in certain populations of Southeast Asia, the Pacific Islands and parts of Africa, but it can appear in individuals of any ethnicity when the responsible gene mutation is inherited.

• Prevalence: Approximately 1–5 % of people of Malay, Thai, Cambodian, and Indonesian descent carry the SAO trait, while the actual disease (homozygous form) is far less common – estimated at 1 in 10,000–30,000 in these regions.<sup>1</sup>
• Age of onset: Because the defect is present from birth, signs may be evident in infancy, but many people remain asymptomatic and are only discovered during routine blood tests.
• Gender: The trait is inherited in an autosomal dominant pattern, so it affects males and females equally.

Symptoms

Most individuals with the heterozygous (carrier) form have no overt symptoms. When symptoms do appear, they are usually mild and related to the altered shape and rigidity of red cells.

Common clinical features

• Hemolytic anemia (mild to moderate): Fatigue, pallor, shortness of breath on exertion, and occasional jaundice.
• Splenomegaly: Enlarged spleen causing abdominal fullness or left‑upper‑quadrant pain.
• Elevated reticulocyte count: The bone marrow produces more young RBCs to compensate for premature destruction.
• Pigmented gallstones: Chronic hemolysis can lead to bilirubin stones in the gallbladder.
• Reduced parasite invasion: Interestingly, carriers have a protective advantage against severe malaria (Plasmodium falciparum), which may mask the condition in endemic regions.<sup>2</sup>

Rare or indirect manifestations

• Episodes of dark urine after infections or certain drugs (hemoglobinuria).
• Iron deficiency due to chronic low‑grade hemolysis.
• Occasional vaso‑occlusive pain crises resembling sickle‑cell disease (very uncommon).

Causes and Risk Factors

Ovalocytosis results from a mutation in the SLC4A1 gene, which encodes the anion exchange protein band 3, a key component of the RBC membrane skeleton.

• Genetic mutation: A single nucleotide change (commonly a 27‑base‑pair deletion) produces an abnormal band 3 protein, causing the cell membrane to become tightly packed and rigid.
• Inheritance pattern: Autosomal dominant – a single abnormal copy of the gene is sufficient to cause the trait. Homozygous individuals (two abnormal copies) have a more severe phenotype.
• Geographic & ethnic background: Higher prevalence in Malay, Thai, Indonesian, Filipino, and some Pacific Islander populations.
• Family history: Having a parent or sibling with the condition significantly increases risk.

Diagnosis

Because many carriers are asymptomatic, diagnosis frequently follows an incidental laboratory finding of abnormal red‑cell morphology.

Laboratory tests

• Complete blood count (CBC): May reveal mild anemia (Hb 10–12 g/dL), elevated reticulocytes, and normal or slightly increased mean corpuscular volume (MCV).
• Peripheral blood smear: The hallmark is uniformly oval, densely stained erythrocytes with reduced central pallor. Cells often appear “stiff” and do not deform in the presence of a microscope slide.
• Osmotic fragility test: Shows decreased fragility (cells are less likely to lyse in hypotonic solutions) – the opposite of hereditary spherocytosis.
• Hemoglobin electrophoresis: Typically normal, helping to rule out hemoglobinopathies.
• Genetic testing: PCR or sequencing of the SLC4A1 gene confirms the specific mutation. This is especially useful for family counseling.

Imaging & other studies (when indicated)

• Abdominal ultrasound: Evaluates spleen size and checks for gallstones if the patient has right‑upper‑quadrant pain.
• Bone‑marrow aspirate: Rarely needed; performed only if anemia is severe and the cause is unclear.

Treatment Options

There is no cure for the genetic defect, but most patients require only supportive care because the disease is often mild.

Medications

• Folic acid supplementation (1 mg daily): Supports red‑cell production, especially in those with chronic hemolysis.
• Iron chelation or supplementation: Guided by ferritin levels; treat iron deficiency if present, but avoid overload.
• Hydroxyurea: Occasionally used in severe cases to reduce hemolysis, though evidence is limited.
• Antimalarial prophylaxis: In malaria‑endemic areas, standard prophylaxis is still recommended; the protective effect of SAO does not eliminate risk.

Procedures

• Splenectomy: Considered only for patients with severe hemolytic anemia, splenomegaly causing symptoms, or frequent transfusion requirements. Post‑splenectomy patients need lifelong vaccination against encapsulated organisms (e.g., Streptococcus pneumoniae).
• Cholecystectomy: Indicated if symptomatic gallstones develop.

Lifestyle and supportive measures

• Stay well‑hydrated to reduce blood viscosity.
• Avoid extreme temperatures and high‑altitude travel if you notice increased fatigue or shortness of breath.
• Limit intake of oxidative drugs (e.g., dapsone, primaquine) that can exacerbate hemolysis.

Living with Ovalocytosis

Most people lead normal lives with minimal restrictions. The following tips help maintain optimal health:

• Regular monitoring: Annual CBC and reticulocyte count; more frequent (every 6 months) if you have anemia or splenomegaly.
• Vaccinations: Keep vaccinations up to date, especially pneumococcal, Haemophilus influenzae type b, and meningococcal vaccines if you have had a splenectomy.
• Healthy diet: Emphasize iron‑rich foods (lean meat, legumes, leafy greens) and folate (citrus fruits, beans). A balanced diet reduces the need for transfusions.
• Exercise: Moderate aerobic activity improves cardiovascular fitness without over‑taxing red‑cell production. If you feel dizzy or excessively fatigued, pause and rest.
• Travel considerations: Carry a medical alert card stating “Ovalocytosis – avoid oxidative medications” and a small supply of folic acid.
• Family planning: Genetic counseling is recommended for couples where both partners are carriers, as there is a 25 % chance of having a child with the homozygous (more severe) form.

Prevention

Because the condition is genetic, primary prevention is not possible. However, secondary prevention—reducing complications—is achievable:

• Screen newborns in high‑prevalence regions with a peripheral smear to identify carriers early.
• Avoid medications known to cause oxidative stress (e.g., sulfa drugs, high‑dose vitamin C) unless prescribed and monitored.
• Prompt treatment of infections (especially malaria) to prevent hemolytic crises.
• Educate at‑risk families about the importance of vaccinations after splenectomy.

Complications

If left unmanaged, ovalocytosis can lead to several health problems, most of which stem from chronic hemolysis:

• Severe anemia: May require transfusion or, rarely, splenectomy.
• Gallstone disease: Pigmented stones causing biliary colic or cholecystitis.
• Increased susceptibility to infections: Particularly with encapsulated bacteria after splenectomy.
• Secondary iron overload: From repeated transfusions; managed with chelation therapy.
• Pregnancy complications: Exacerbated anemia can increase the risk of preterm birth or low birth weight; close obstetric monitoring is essential.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:

• Sudden, severe abdominal pain especially in the upper right quadrant (possible gallstone complication).
• Rapid onset of dark urine, jaundice, or marked yellowing of the skin and eyes (acute hemolytic crisis).
• High fever (>38.5 °C / 101.3 °F) with chills and a rapid heart rate, suggesting infection after splenectomy.
• Severe shortness of breath, chest pain, or dizziness after exertion – could indicate profound anemia or cardiac strain.
• Uncontrolled bleeding or bruising that cannot be stopped.

These signs require immediate medical evaluation to prevent life‑threatening complications.

References

1. Mayo Clinic. “Southeast Asian Ovalocytosis.” Updated 2023. https://www.mayoclinic.org
2. World Health Organization. “Malaria and Genetic Red Cell Disorders.” WHO Technical Report Series, 2022.
3. National Institutes of Health (NIH). “SLC4A1 Gene.” GeneReviews®; Updated 2021. https://www.ncbi.nlm.nih.gov
4. Cleveland Clinic. “Hemolytic Anemia.” Patient Education. 2024.
5. CDC. “Guidelines for Prevention and Management of Infections in Asplenic Persons.” 2023.

```